Immunovant's IMVT-1402 wins at higher dose only in hard-to-treat arthritis; Sjögren's ambitions curbed

Immunovant's lead pipeline asset has a positive result in one indication and a narrower outlook in another. On 9 November 2026 the company said the 600 mg dose of IMVT-1402 outperformed placebo in the randomised-withdrawal portion of a potentially registrational study in rheumatoid arthritis patients who have not responded well to existing therapies. The measure was ACR20 response at Week 28.

In that portion of the trial, 92.5% of patients on 600 mg met the ACR20 threshold, compared with 75.6% on placebo. The 300 mg dose did not show a difference from placebo. That leaves a single dose carrying the efficacy case, a point likely to matter when the company sets out a development plan to regulators.

Immunovant intends to talk to the US Food and Drug Administration about the route to registration in this setting later this year. The company's disclosure does not say what those discussions will cover, so it is not yet clear whether the current study could underpin a filing.

The company also said it now regards further development of IMVT-1402 in Sjögren's disease, beyond the Phase 2 study already under way, as unlikely. That reduces the number of late-stage indications the molecule is expected to pursue in the near term.

On the financial side, Immunovant reported cash of $722.3 million at the end of the quarter and a net loss of $97.2 million for the three months to 30 September 2026.